A phase III trial of bevasiranib, a treatment for wet age-related macular degeneration and the most advanced RNAi drug candidate in human testing, has been halted early after being deemed "unlikely" to meet its primary endpoint, the therapy's developer said last week.

According to Opko Health, the trial's independent data-monitoring committee had recommended ending the study after reviewing preliminary data, which "showed activity of bevasiranib … [but] indicated that the trial, as structured, was unlikely to meet its primary endpoint."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.